文献速递胸部肿瘤乳腺癌头颈与中枢神经肿瘤

质子全脑全脊髓照射对比光子累及野放疗治疗实体瘤软脑膜转移的随机II期试验

Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.
PubMed 文献 · J Clin Oncol · 2022-07-08

该随机II期试验比较质子全脑全脊髓照射(pCSI)与光子累及野放疗(IFRT)在非小细胞肺癌和乳腺癌软脑膜转移(LM)患者中的疗效,pCSI组42例、IFRT组21例。pCSI组中位中枢神经系统无进展生存期(CNS PFS)为7.5个月,优于IFRT组的2.3个月(P<.001);pCSI组中位总生存期(OS)为9.9个月,优于IFRT组的6.0个月(P=.029);两组3级和4级治疗相关不良事件(TAEs)发生率无差异(P=.19)。

要点

  • 在非小细胞肺癌和乳腺癌LM患者中,pCSI较光子IFRT显著改善CNS PFS(中位7.5个月 vs 2.3个月,P<.001)。
  • pCSI组中位OS为9.9个月,优于IFRT组的6.0个月(P=.029)。
  • 两组3级和4级TAEs发生率无差异(P=.19)。

核心结论

  • 与光子IFRT相比,pCSI改善了非小细胞肺癌和乳腺癌LM患者的CNS PFS和OS,且未增加严重TAEs。

研究设计与样本

  • 随机II期试验,比较pCSI与IFRT在非小细胞肺癌和乳腺癌LM患者中的疗效,另设其他实体瘤探索性pCSI组。
  • 随机组按2:1分配至pCSI或IFRT,按组织学和系统性疾病状态分层。
  • 2020年4月16日至2021年10月11日期间,42例和21例患者分别随机分配至pCSI组和IFRT组。
  • 探索性pCSI组纳入35例患者。
  • 主要终点为CNS PFS,次要终点包括OS和TAEs。

主要发现

  • pCSI组中位CNS PFS为7.5个月(95%CI,6.6个月至未达到),IFRT组为2.3个月(95%CI,1.2至5.8个月),差异显著(P<.001)。
  • pCSI组中位OS为9.9个月(95%CI,7.5个月至未达到),IFRT组为6.0个月(95%CI,3.9个月至未达到),差异显著(P=.029)。
  • 两组3级和4级TAEs发生率无差异(P=.19)。
  • 探索性pCSI组中位CNS PFS为5.8个月(95%CI,4.4至9.1个月),中位OS为6.6个月(95%CI,5.4至11个月)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Photon involved-field radiotherapy (IFRT) is the standard-of-care radiotherapy for patients with leptomeningeal metastasis (LM) from solid tumors. We tested whether proton craniospinal irradiation (pCSI) encompassing the entire CNS would result in superior CNS progression-free survival (PFS) compared with IFRT. PATIENTS AND METHODS: We conducted a randomized, phase II trial of pCSI versus IFRT in patients with non-small-cell lung cancer and breast cancers with LM. We enrolled patients with other solid tumors to an exploratory pCSI group. For the randomized groups, patients were assigned (2:1), stratified by histology and systemic disease status, to pCSI or IFRT. The primary end point was CNS PFS. Secondary end points included overall survival (OS) and treatment-related adverse events (TAEs). RESULTS: Between April 16, 2020, and October 11, 2021, 42 and 21 patients were randomly assigned to pCSI and IFRT, respectively. At planned interim analysis, a significant benefit in CNS PFS was observed with pCSI (median 7.5 months; 95% CI, 6.6 months to not reached) compared with IFRT (2.3 months; 95% CI, 1.2 to 5.8 months; P < .001). We also observed OS benefit with pCSI (9.9 months; 95% CI, 7.5 months to not reached) versus IFRT (6.0 months; 95% CI, 3.9 months to not reached; P = .029). There was no difference in the rate of grade 3 and 4 TAEs (P = .19). In the exploratory pCSI group, 35 patients enrolled, the median CNS PFS was 5.8 months (95% CI, 4.4 to 9.1 months) and OS was 6.6 months (95% CI, 5.4 to 11 months). CONCLUSION: Compared with photon IFRT, we found pCSI improved CNS PFS and OS for patients with non-small-cell lung cancer and breast cancer with LM with no increase in serious TAEs.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yang JT, Wijetunga NA, Pentsova E, et al. Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis. J Clin Oncol. 2022. PMID: 35802849. doi:10.1200/JCO.22.01148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。